Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission (EC) has approved Pfizer's pneumococcal polysaccharide conjugate vaccine - Prevenar 13 - as an extended use drug for adults aged 50 and older to treat invasive pneumococcal disease caused by Streptococcus pneumoniae.
Subscribe to our email newsletter
The approval of Prevenar 13 was based on the review of clinical immunogenicity and safety data involving more than 6,000 adults aged 50 years and older.
Prevenar 13 uses company-pioneered conjugation technology and prevents invasive pneumococcal disease caused by the 13 serotypes contained in the vaccine and is for a single dose.